compani lly- et intra-day price
sweet simpl still like rais quarter
invest summari beat rais maintain ow rate
pt share continu sale growth margin expans pipelin
advanc off-set competit older product view
therefor think multipl expans upward earn revis drive
takeaway support posit thesi carmelina
trial met primari endpoint tradjenta demonstr cv safeti compar
placebo type diabet patient publish phase
baricitinib result sle phase studi flortaucipir
 met two primari endpoint initi ixora-r
head-to-head clinic trial evalu superior taltz tremfya
ema chmp issu posit opinion emgal
fda announc approv emgal mg inject
prevent treatment migrain adult yesterday announc
trulic met primari efficaci object rewind clinic trial
significantli reduc mace announc result phase
clinic trial dual gip receptor agonist ra
show strong clinic meaning blood sugar reduct
weight loss peopl type diabet phase studi type diabet
expect begin later earli complet late
elanco becam publicli trade compani via ipo close
ipo own elanco activ work divest
remain posit tax-effici transact within one year ipo
report adjust dilut ep factset
consensu higher estim increas ep
guidanc factset consensu
ep rais midpoint versu ep beat quarter
updat model result increas ep
 valuat use blend dcf multipl ev/ebitda analysi get
price target
disclosur section may found page
use blend dcf multipl ev/ebitda analysi get price
target
greater expect brand and/or gener competit lilli key drugs/product
number lilli top-sel human pharmaceut product recent lost
lose next sever year signific patent protect and/or data protect
well key countri outsid certain signific product longer
effect exclus patent protect data protect non-biolog product
loss exclus whether expir consequ litig typic result
entri one gener competitor lead rapid sever declin
revenu especi histor outsid market penetr gener
follow loss exclus rapid pervas howev gener
market penetr increas mani market outsid includ japan europ
mani countri emerg market biolog humalog humulin erbitux
cyramza trulic taltz loss exclus may may result near-term entri
competitor version biosimilar due develop timelin manufactur challeng
and/or uncertainti regulatori pathway approv competitor version
setback lilli pipelin could headwind compani futur growth prospect
lilli compet larg number multi-national pharmaceut compani biotechnolog
compani gener pharmaceut compani compet success lilli must
continu deliv market innov cost-effect product meet import medic
lilli human pharmaceut busi subject increas govern price control
public privat restrict price reimburs access drug
could materi advers effect busi public privat payer take
increasingli aggress step control expenditur human pharmaceut
place restrict price reimburs patient access lilli medic
pressur could neg affect futur revenu net incom lilli expect
price reimburs access pressur govern privat payer insid
outsid becom sever
manufactur difficulti disrupt could lead product suppli problem
anim health manufactur complex highli regul
manufactur difficulti lilli facil contract facil failur refus
contract manufactur suppli contract quantiti could result product shortag
lead lost revenu difficulti disrupt could result qualiti regulatori
complianc problem natur disast mechan inform technolog system failur
inabl obtain sole-sourc raw intermedi materi addit given difficulti
predict sale new product long lead time necessari expans
regulatori qualif pharmaceut manufactur capac possibl lilli
could difficulti meet unanticip demand new product
bull bear base case analysi
also use blend dcf multipl ev/ebitda analysi arriv bull
bear case scenario base analysi estim likelihood stock worth
next month
exhibit bull bear base case scenario analysi
cantor fitzgerald research compani reportsbul casesal trulic jardianc taltz verzenio key drug exceed expectationspipelin advanc exceed expectationsstrateg accret scenario casesal trulic jardianc taltz verzenio key drug line expectationspipelin advanc line expectationsno scenario casesal trulic jardianc taltz verzenio key drug expectationspipelin advanc expectationsno scenario exhibit varianc analysi
amount chang yoyamount chang yoyvariancecommentstot increas volum new pharmaceut product trulic basaglar olumi taltz manufactur effici effect foreign exchang rate favor impact product mix gross reduc expens late life-cycl product action taken reduc cost lower develop mileston payment action taken reduc cost structur oper non oper pre-tax tax adjust net averag adjust dilut cantor fitzgerald research compani reportsactualcantor
exhibit catalyst event calendar
datedriverupcom november/decemb galcanezumab eu abemaciclib keytrudaphas data hr breast cancer kra nsclc non-squam nsclcdecemb lillyinvestor day expect guidanc pipelin initi psoriat initi chronic kidney premetrex patent litig ipr appeal galcanezumab us regulatori file cluster premetrex regulatori action snda includ data ixekizumab us regulatori file axial spondyloarthritisyear-end kinase/mtor dual inhibitor prostat readoutl agonist phase surpass initi type diabet monotherapi late agonist phase surpass initi type diabet vs semaglutid late agonist phase surpass initi type diabet vs degludec late agonist phase surpass initi type diabet vs glargin establish cvd late agonist phase surpass initi type diabet basal insulin add-on late agonist phase surpass japan monotherapi initi type diabetesl agonist phase surpass japan oad combin initi type diabetesl agonist initi surpass cvot event driven power cv ixekizumab eu regulatori file axial spondyloarthritissourc cantor fitzgerald research compani report exhibit catalyst event calendar continu
datedriverupcom ixekizumab complet trial versu humira psoriat phase data oa/clbp phase data oa/clbp safeti data oa/clbp pain us eu marketsjun dulaglutid present detail rewind result ada scientif data parkinson diseas ramucirumab merestinib data pivot phase trial biliari tract canceraugust exclus europ ramucirumab phase top-lin relay data egfr nsclc top-lin data carolina cv outcom dulaglutid submit rewind data regulatori result empris remain ownership interest agonist present titrat studi data help manag gi side pegyl nsclc rapid lispropres detail phase result regulatori linagliptan metformin xrregulatori submiss phase readout atop studi overcom avail baselin addit dose phase studi phase emperial-preserv outcom trial chronic phase emperial-reduc outcom trial chronic readout crohn readout solid olaratumab phase announc data soft tissu sarcoma combo doxorubicinend ixekizumab complet ixora-r trial versu tremfya moderate-to-sever plaqu readout cancer dulaglutid label updat rewind phase emperor hf-preserv outcom trial chronic phase emperor hf-reduc outcom trial chronic phase empa-kidney outcom trial chronic kidney data monotherapi alzheim deposit mabphas data alzheim readout dian readout solid abemaciclib result adjuv studi hr breast premetrex eu loss premetrex japan loss exclusivityl agonist complet phase surpass studi type agonist potenti global studi overcom end data premetrex patent expir loss pediatr exclus abemaciclib nce exclus readout aspirinu patent dulaglutid patent agonist data surpass cvot event driven power cv patent patent jentaduet patent ramucirumab patent ixekizumab patent olaratumab eu loss olaratumab patent abemaciclib patent baricitinib eu patent baricitinib patent ixekizumab eu loss baricitinib japan patent galcanezumab patent expirationsourc cantor fitzgerald research compani report exhibit cantor estim versu manag guidanc
exhibit incom statement analysi
exhibit margin analysi
exhibit quarterli sale analysi
exhibit annual sale analysi
exhibit analysi
exhibit balanc sheet analysi
 co engag discoveri develop manufactur sale pharmaceut product oper two segment
product anim health product segment includ discoveri develop
manufactur market sale human pharmaceut product world-wide follow therapeut area neurosci
endocrinolog oncolog cardiovascular anim health segment oper divis
develop manufactur market product food companion anim anim health product includ rumensin tylan
posilac paylean product livestock poultri well trifexi comforti product companion anim
